Immuno-PET Imaging of CD93 Expression with ⁶⁴Cu-Radiolabeled NOTA-mCD93 ([⁶⁴Cu]Cu-NOTA-mCD93) and Insulin-Like Growth Factor Binding Protein 7 ([⁶⁴Cu]Cu-NOTA-IGFBP7).

ABSTRACT: CD93 is overexpressed in multiple solid tumor types, serving as a novel target for antiangiogenic therapy. The goal of this study was to develop a ⁶⁴Cu-based positron emission tomography (PET) tracer for noninvasive imaging of CD93 expression. Antimouse-CD93 mAb (mCD93) and the CD93 ligand IGFBP7 were conjugated to a bifunctional chelator, p-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-NOTA) and labeled with ⁶⁴Cu. To evaluate the pharmacokinetic properties and tumor-targeting efficacy of [⁶⁴Cu]Cu-NOTA-mCD93 and [⁶⁴Cu]Cu-NOTA-IGFBP7, PET imaging and biodistribution were performed on both 4T1 murine breast tumor-bearing mice and MDA-MB-231 human breast tumor-bearing mice. The tumor model HT1080-FAP, which d

SUBMITTER: Li X 

PROVIDER: S-EPMC11832137 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature